Sentry Investment Management LLC Buys 469 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sentry Investment Management LLC increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 85.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,020 shares of the medical equipment provider’s stock after buying an additional 469 shares during the period. Sentry Investment Management LLC’s holdings in Zimmer Biomet were worth $110,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Crewe Advisors LLC acquired a new position in shares of Zimmer Biomet in the first quarter valued at approximately $31,000. Bangor Savings Bank bought a new position in Zimmer Biomet during the 3rd quarter worth $31,000. Family Firm Inc. acquired a new stake in shares of Zimmer Biomet during the second quarter worth $33,000. J.Safra Asset Management Corp grew its stake in shares of Zimmer Biomet by 712.1% in the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 235 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in Zimmer Biomet during the 2nd quarter worth $43,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on ZBH. Morgan Stanley reduced their price target on shares of Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. TD Cowen lowered their price target on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. Canaccord Genuity Group reduced their price objective on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Citigroup decreased their target price on Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Finally, Truist Financial increased their target price on shares of Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a report on Friday, November 1st. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $124.11.

Zimmer Biomet Stock Up 0.5 %

Zimmer Biomet stock opened at $108.92 on Wednesday. The firm has a 50 day moving average price of $106.72 and a two-hundred day moving average price of $110.58. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90. The firm has a market cap of $21.68 billion, a price-to-earnings ratio of 20.71, a PEG ratio of 1.99 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter last year, the firm earned $1.65 earnings per share. Zimmer Biomet’s quarterly revenue was up 4.1% on a year-over-year basis. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were issued a $0.24 dividend. The ex-dividend date was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. Zimmer Biomet’s payout ratio is currently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.